Le Moing V - Search Results

1

High prevalence of undiagnosed COPD in a cohort of HIV-infected smokers.

Makinson A, Hayot M, Eymard-Duvernay S, Quesnoy M, Raffi F, Thirard L, Bonnet F, Tattevin P, Abgrall S, Quantin X, Léna H, Bommart S, Reynes J, Le Moing V; ANRS EP48 HIV CHEST Study Team. Makinson A, et al. Among authors: le moing v. Eur Respir J. 2015 Mar;45(3):828-31. doi: 10.1183/09031936.00154914. Epub 2014 Oct 16. Eur Respir J. 2015. PMID: 25323226 Free article. No abstract available.

2

Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group.

Savès M, Raffi F, Clevenbergh P, Marchou B, Waldner-Combernoux A, Morlat P, Le Moing V, Rivière C, Chêne G, Leport C. Savès M, et al. Among authors: le moing v. Antimicrob Agents Chemother. 2000 Dec;44(12):3451-5. doi: 10.1128/AAC.44.12.3451-3455.2000. Antimicrob Agents Chemother. 2000. PMID: 11083658 Free PMC article.

3

Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: secondary prophylaxis.

Abgrall S, Matheron S, Le Moing V, Dupont C, Costagliola D; Clinical Epidemiology Group from the French Hospital Database on HIV. Abgrall S, et al. Among authors: le moing v. J Acquir Immune Defic Syndr. 2001 Feb 1;26(2):151-8. doi: 10.1097/00042560-200102010-00007. J Acquir Immune Defic Syndr. 2001. PMID: 11242182

4

Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors.

Le Moing V, Chêne G, Carrieri MP, Besnier JM, Masquelier B, Salamon R, Bazin C, Moatti JP, Raffi F, Leport C; APROCO Study Group. Le Moing V, et al. J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):372-6. doi: 10.1097/00126334-200108010-00007. J Acquir Immune Defic Syndr. 2001. PMID: 11468425

5

The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort.

Carrieri P, Cailleton V, Le Moing V, Spire B, Dellamonica P, Bouvet E, Raffi F, Journot V, Moatti JP; APROCO study group. Carrieri P, et al. Among authors: le moing v. J Acquir Immune Defic Syndr. 2001 Nov 1;28(3):232-9. doi: 10.1097/00042560-200111010-00005. J Acquir Immune Defic Syndr. 2001. PMID: 11694829

6

Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients.

Le Moing V, Chêne G, Leport C, Lewden C, Duran S, Garré M, Masquelier B, Dupon M, Raffi F; Antiprotéases Cohorte (APROCO) Study Group. Le Moing V, et al. Clin Infect Dis. 2002 Jan 15;34(2):239-47. doi: 10.1086/324354. Epub 2001 Dec 4. Clin Infect Dis. 2002. PMID: 11740714

7

Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients.

Le Moing V, Peytavin G, Journot V, Cottalorda J, Bouvet E, Chêne G, Préau M, de Boever CM, Leport C, Raffi F; Antiprotease Cohort (APROCO) Study Group. Le Moing V, et al. J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):497-9. doi: 10.1097/00126334-200312150-00008. J Acquir Immune Defic Syndr. 2003. PMID: 14657760

8

T-Cell surface CCR5 density is not correlated with hepatitis severity in hepatitis C virus/HIV-coinfected individuals: implications for the therapeutic use of CCR5 antagonists.

Vincent T, Portales P, Baillat V, de Boever CM, Le Moing V, Vidal M, Ducos J, Clot J, Reynes J, Corbeau P. Vincent T, et al. Among authors: le moing v. J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):305-9. J Acquir Immune Defic Syndr. 2005. PMID: 15735449

9

[Assessment of renal abnormalities in 107 HIV patients treated with tenofovir].

Lochet P, Peyrière H, Le Moing V, Blayac JP, Hansel S, Reynes J. Lochet P, et al. Among authors: le moing v. Therapie. 2005 Mar-Apr;60(2):175-81. doi: 10.2515/therapie:2005022. Therapie. 2005. PMID: 15969320 French.

10

[Outcome of HIV-infected patients after 5 years of antiretroviral therapy including a protease inhibitor: the Aproco/Copilote Cohort].

Le Moing V, Chêne G, Spire B, Raffi F, Leport C; Groupe d'étude Aproco/Copilote. Le Moing V, et al. Presse Med. 2005 Jun 4;34(10 Suppl):1S31-7. Presse Med. 2005. PMID: 16025665 French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

281 results

Search Page